A Randomized, Multicenter, Phase II Study of Docetaxel and TS-1 Combination as a First-Line Treatment in Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

Trial Profile

A Randomized, Multicenter, Phase II Study of Docetaxel and TS-1 Combination as a First-Line Treatment in Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2011

At a glance

  • Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2011 Planned end date changed from 1 Jun 2012 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 25 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top